ClinicalTrials.gg

Program

rusfertide

Also written as “PTG-300”, “Rusfertide” and “Open-label rusfertide”.

Its studies are mostly in Polycythemia Vera · Thalassemia · Hemochromatosis, led by 2 companies.

Furthest: phase 3, since Jan 14, 202210 company-led studies, 4 open or runningNext primary completion: Oct 28, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Protagonist Therapeutics82 open or runningphase 3since Jan 14, 2022Jan 9, 2019none ahead
Takeda22 open or runningphase 2since Jun 10, 2026Jun 10, 2026Oct 28, 2027phase 2 · NCT07648030

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 9, 2019First study: phase 2 study in β-thalassemiaNew to Protagonist TherapeuticsProtagonist Therapeutics · NCT03802201 · 63 enrolled · United States, Greece, Italy and more
  2. Aug 7, 20192 phase 2 studiesProtagonist Therapeutics · NCT04057040, NCT04054921
  3. Dec 16, 2019Phase 2 study in HemochromatosisProtagonist Therapeutics · NCT04202965 · 16 enrolled · United States, Canada
  4. Aug 10, 2020Phase 1 study in Healthy VolunteersProtagonist Therapeutics · NCT04516382 · 12 enrolled · Australia
  5. Feb 18, 2021Phase 2 study in Polycythemia VeraProtagonist Therapeutics · NCT04767802 · 20 enrolled · Korea, Republic of, Malaysia
  6. Jan 14, 2022Phase 3 study in Polycythemia VeraProtagonist Therapeutics · NCT05210790 · 293 enrolled · United States, Australia, Austria and more
  7. Sep 5, 2023Phase 3 study in Polycythemia VeraProtagonist Therapeutics · NCT06033586 · 46 enrolled · United States
  8. Jun 10, 2026Takeda's first study: phase 2 study in Polycythemia VeraNew to TakedaTakeda · NCT07648030 · 9 planned · Japan
  9. Aug 11, 2026Phase 2 study in Polycythemia VeraTakeda · NCT07765602 · 24 planned

Ahead

  1. Oct 28, 2027Primary completion: phase 2 study in Polycythemia VeraTakeda · NCT07648030
  2. Jul 1, 2028Primary completion: phase 2 study in Polycythemia VeraTakeda · NCT07765602

TargetBeta

HAMP →read by rule
“An injectable peptide mimetic of hepcidin (hepcidin antimicrobial peptide; HAMP; putative liver tumor regressor; PLTR; liver-expressed antimicrobial peptide 1; LEAP-1) ”NCIt, by rule

Studies

All 10 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07765602Polycythemia Vera2Not yet recruitingTakedaJul 1, 202824
NCT07648030Polycythemia Vera · Japan2RecruitingTakedaOct 28, 20279
NCT06033586Polycythemia Vera · United States3Active, not recruitingProtagonist TherapeuticsApr 1, 202646
NCT05210790Polycythemia Vera · United States, Australia, Austria and more3Active, not recruitingProtagonist TherapeuticsFeb 21, 2025293
NCT04767802Polycythemia Vera · Korea, Republic of, Malaysia2CompletedProtagonist TherapeuticsMar 15, 202320
NCT04516382Healthy Volunteers · Australia1CompletedProtagonist TherapeuticsJan 12, 202112
NCT04202965Hemochromatosis · United States, Canada2CompletedProtagonist TherapeuticsOct 6, 202116
NCT04054921β-thalassemia · United States, Greece, Lebanon and more2CompletedProtagonist TherapeuticsJul 31, 202034
NCT04057040Polycythemia Vera · United States, India2CompletedProtagonist TherapeuticsFeb 14, 202370
NCT03802201β-thalassemia · United States, Greece, Italy and more2CompletedProtagonist TherapeuticsJul 31, 202063

How it is read

Names in the registry

  • “PTG-300”, 6 entries
  • “Rusfertide”, 3 entries
  • “Open-label rusfertide”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.